New Risk • 53m
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 102% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Jun 28
New major risk - Revenue and earnings growth Earnings have declined by 102% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 102% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$10.8m market cap). 공시 • Jun 05
Basel Medical Group Ltd Announces CFO Changes The Board of Directors of Basel Medical Group Ltd. has appointed Mr. Neo Chun How Alton as its new interim Chief Financial Officer effective June 2, 2026. Mr. Neo was appointed as interim CFO to replace Ms. Jianing Lu, the CFO of the Company. Ms. Lu resigned from her position as CFO of the Company. Mr. Neo is a finance professional with extensive experience in corporate leadership, financial management, and education. Prior to joining Basel Medical, Alton served as the deputy CEO of InCorp Global's Singapore operations, where he oversaw the entire Singapore's operations - in particular, advisory and outsourcing services. In this role, he provides expertise in management reporting, corporate restructuring, business valuation, insolvency, and forensic accounting. Before his tenure at InCorp Global, Mr. Neo contributed to the Singapore Ministry of Finance as a tax policy associate, focusing on the development and review of tax incentives. He was also part of the pioneer team at the Singapore Accountancy Commission (now ACRA) that developed the Singapore Chartered Accountant Qualification Programme. In addition to his corporate roles, Mr. Neo is dedicated to education, having developed and taught courses in financial accounting and related subjects at leading tertiary institutions. Currently, he serves as a part-time tutor at the London School of Business & Finance in Singapore and Singapore University of Social Sciences. Mr. Neo holds a Master of Business Administration, University of Hull and is also a Chartered Valuer, Institute of Valuers and Appraisers, CA Singapore, Institute of Singapore Chartered Accountants and CPA Australia. Reported Earnings • Mar 17
Full year 2025 earnings released: S$0.64 loss per share (vs S$0.13 profit in FY 2024) Full year 2025 results: S$0.64 loss per share (down from S$0.13 profit in FY 2024). Revenue: S$12.1m (up 16% from FY 2024). Net loss: S$12.1m (down S$14.2m from profit in FY 2024). Board Change • Jan 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Group CFO & Director Jianing Lu is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Dec 04
Basel Medical Group Receives Delinquency Notification from Nasdaq Basel Medical Group Ltd. announced that it has received notification from Nasdaq that the Company’s annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company’s auditor, NLA DFK Assurance PAC, on the Company’s financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial statements. Under Nasdaq rules, the Company now has 60 calendar days to submit a plan to regain compliance and if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original filing’s due date may be granted, or until May 18, 2026, to regain compliance. In determining whether to accept such plan, Nasdaq will consider such things as the likelihood that the filing, along with any subsequent periodic filing that will be due, can be made within the 180 day period, the Company’s past compliance history, the reasons for the late filing, other corporate events that may occur within review period, the Company’s overall financial condition and its public disclosures. Any subsequent periodic filing that is due within the 180 day exception period must be filed no later than the end of the period. If the plan to regain compliance is not accepted, the Company will have the opportunity to appeal that decision to a Hearings Panel. The Company is currently working with its accounting, audit and legal professionals to prepare a rectification plan to remedy the above mentioned non-compliance. Trading of the Company’s shares on Nasdaq is not currently affected by such non-compliance. 